| Symbol | GBIM |
|---|---|
| Name | GLOBEIMMUNE, INC. |
| Sector | UNDEFINED |
| Region | North America |
| Industry | - |
| Address | 80027 United States CO 1450 Infinite Drive |
| Telephone | 303 625 2700 |
| Fax | — |
| — | |
| Website | https://globeimmune.com |
| Incorporation | US |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | — |
| Audit Status | NOT AVAILABLE |
| Reporting Status | Dark: Alternative Reporting Standard |
| CIK | 0001245104 |
| Description | We are a biopharmaceutical company established in 1995 focused on developing products for the treatment of cancer and infectious diseases based on our proprietary Tarmogen(R) platform. Tarmogens activate the immune system by stimulating a subset of white blood cells called T cells that destroy infected or malignant cells, in contrast to traditional vaccines which predominately stimulate antibody production. We believe that our Tarmogen platform has applicability to a number of diseases, and may enable us to develop a broad portfolio of products. Additional info from OTC: |
No news found.